Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

A randomised trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML

Single infusion of cilta-cel sees longer median PFS than any previously reported therapy in heavily pretreated RRMM

Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL

Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL

Ponatinib superior to imatinib in combination with reduced-intensity chemotherapy in newly diagnosed Ph positive ALL

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

ASCO 2023: Highlights and analysis

ASCO 2023: Latest in PARP inhibitors in prostate cancer